>>Signaling Pathways>> Angiogenesis>> BTK>>Evobrutinib (M2951)

Evobrutinib (M2951)

Catalog No.GC34062

Evobrutinib는 구강으로 복용 가능한, 고도로 선택적인 결합형 브루톤 티로신 키나아제 억제제로서 잘 내약성이 있으며 효과적입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Evobrutinib (M2951) Chemical Structure

Cas No.: 1415823-73-2

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$96.00
재고 있음
1mg
US$56.00
재고 있음
5mg
US$101.00
재고 있음
10mg
US$166.00
재고 있음
50mg
US$588.00
재고 있음
100mg
US$1,011.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Evobrutinib, as an orally, highly selective, covalent Bruton's tyrosine kinase inhibitor, was well‐tolerated and effective.[1] Evobrutinib was metabolized via hydroxylation, hydrolysis, O-dealkylation, glucuronidation, and GSH conjugation.[4]

n vitro efficacy test it shown that evobrutinib inhibits Btk in vitro with IC50 values in two studies 58 nM and 38 nM. Evobrutinib at concentrations of 10 µM did not increase bleeding time in vitro. [5] In U937 NF-κB–Luc reporter cells, evobrutinib inhibited NF-κB activation and, FcγR signaling with an IC50 of 78 nM. Evobrutinib inhibited BTK and BMX with IC50 values of 0.058 μM and 0.02 μM, respectively. Evobrutinib inhibited B cell activation in PBMCs with a mean IC50 of 15.8 nM. Evobrutinib inhibited basophil activation with an average IC50 of 1.66 μM. [2] In vitro, treatment with 100 to 1000 nM evobrutinib dose-dependently reduced calcium mobilization upon BCR ligation in a manner indistinguishable from the murine setting, while T cells again remained unaffected. In addition, production of IL-6, IFN-γ and IL-10 upon BCR ligation was reduced by 1000 nM evobrutinib.[3]

In vivo, treatment with 1, 3 or 10 mg/kg evobrutinib in C57/BL6 mice orally inhibited expression of molecules involved in B-cell antigen presentation. Evobrutinib treatment (10 mg/kg) functionally impaired the capacity of B cells to act as antigen-presenting cells for the development of encephalitogenic T cells, resulting in a remarkably decreased disease severity in mice.[3]

References:
[1]Scheible H, et al. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. Clin Transl Sci. 2021 Nov;14(6):2420-2430. 
[2]Haselmayer P, et al. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. J Immunol. 2019 May 15;202(10):2888-2906.
[3]Torke S, et al. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020 Oct;140(4):535-548. 
[4]Li Z, et al. Identification of metabolites of evobrutinib in rat and human hepatocytes by using ultra-high performance liquid chromatography coupled with diode array detector and Q Exactive Orbitrap tandem mass spectrometry. Drug Test Anal. 2019 Jan;11(1):129-139. 
[5]von Hundelshausen P, et al. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. Cancers (Basel). 2021 Mar 4;13(5):1103.

리뷰

Review for Evobrutinib (M2951)

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Evobrutinib (M2951)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.